Louisiana Heart Center | Covington, LA

Research site

(Unclaimed)

Location

39 Starbrush Circle, Covington, Louisiana, United States of America

Site insights

Top conditions

Top treatments

Semaglutide

EMPagliflozin

Sugar

JK07

Droxidopa

Cholesterol

Zenagamtide

Ranolazine

Inclisiran

sodium

Parent organization

This site is a part of Louisiana Heart Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 10 total trials

New

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity (AMBIENCE)

This clinical study is being conducted to evaluate the safety and effectiveness of zenagamtide in people with atherosclerotic cardiovascular disease...

Begins enrollment this month

Obesity

Cardiovascular Risk

Drug: Zenagamtide

Drug: Placebo

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diab...

Enrolling

Cardiovascular Risk

Type 2 Diabetes

Drug: Zenagamtide

Drug: Insulin glargine U-100

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)

V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous co...

Enrolling

Peripheral Endovascular Intervention

Percutaneous Coronary Intervention

Drug: Normal Saline (Placebo)

Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular...

Active, not recruiting

Cardiovascular Disease

Drug: Cagrilintide

Drug: Semaglutide

Study of JK07 in Patients With Chronic Heart Failure (RENEU-HF)

This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in part...

Active, not recruiting

Heart Failure With Preserved Ejection Fraction

Heart Failure With Reduced Ejection Fraction

Drug: JK07

Drug: Placebo